Ablation versus resection for resectable colorectal liver metastases - Health care related cost and survival analyses from a quasi-randomised study. Issue 2 (February 2023)

• Record Type: Journal Article
• Authors: Tinguely, Pascale; Laurell, Gustaf; Enander, Anton; Engstrand, Jennie; Freedman, Jacob
• Is Part Of: European journal of surgical oncology. Volume 49:Issue 2(2023)
• Page Start: 416
• Page End: 425
• Publication Date: 2023-02
• Subjects: Liver -- Neoplasm metastasis -- Ablation techniques -- Hepatectomy -- Healthcare costs -- Survival analysis; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2022.09.006
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Background: The aim of this study was to compare healthcare related costs and survival in patients treated with microwave ablation (MWA) versus surgical resection for resectable colorectal liver metastases (CRLM), in patients from a quasi-randomised setting. Methods: The Swedish subset of data from a prospective multi-centre study investigating survival after percutaneous computer-assisted M icrowave A blation VE rsus R esection for R esectabl e C RLM (MAVERRIC study) was analysed. Patients with CRLM ≤ 3 cm amenable to ablation and resection were considered for study inclusion only on even calendar weeks, while treated with gold standard resection every other week, creating a quasi-randomised setting. Survival and costs (all inpatient hospital admissions, outpatient visits, oncological treatments and radiological imaging) in the 2 years following treatment were investigated. Results: MWA (n = 52) and resection (n = 53) cohorts had similar baseline patient and tumour characteristics and health care consumption within 1 year prior to CRLM treatment. Treatment related morbidity and length of stay were significantly higher in the resected cohort. Overall health care related costs from decision of treatment and 2 years thereafter were lower in the MWA versus resection cohort (mean ± SD USD 80′964±59′182 versus 110′059±59′671, P < 0.01). Five-year overall survival was 50% versus 54% in MWA versus resection groups (P = 0.95). Conclusions: MWA is associated with decreased morbidity, time spent in medical facilities and healthcare related costs within 2 years of initial treatment with equal overall survival, highlighting its benefits for patient and health care systems.